source
- Novo Nordisk’s oral Wegovy sales beat forecasts, boosting shares over 5%BioPharma Dive’s latest visualization series examines how investors reacted to three drug launches highlighted in recent quarterly earnings. Novo Nordisk reported that its oral Wegovy generated 5.…
- Agios cuts over 35% of R&D staff as FDA decision on sickle cell drug is delayedAgios announced it will eliminate more than 100 R&D positions, representing over a third of its research staff, after the FDA postponed a decision on its sickle cell disease candidate. The company…